Magnus Financial Group LLC Invests $233,000 in Danaher Co. (NYSE:DHR)

Magnus Financial Group LLC bought a new position in shares of Danaher Co. (NYSE:DHR) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 837 shares of the conglomerate’s stock, valued at approximately $233,000.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Vanguard Group Inc. raised its position in Danaher by 7.4% during the first quarter. Vanguard Group Inc. now owns 60,107,030 shares of the conglomerate’s stock valued at $15,009,928,000 after buying an additional 4,163,657 shares during the period. Legal & General Group Plc raised its position in Danaher by 2.4% during the second quarter. Legal & General Group Plc now owns 5,964,031 shares of the conglomerate’s stock valued at $1,490,112,000 after buying an additional 139,989 shares during the period. Capital Research Global Investors raised its position in Danaher by 1.0% during the first quarter. Capital Research Global Investors now owns 5,125,470 shares of the conglomerate’s stock valued at $1,279,932,000 after buying an additional 52,679 shares during the period. Dimensional Fund Advisors LP raised its position in Danaher by 2.6% during the second quarter. Dimensional Fund Advisors LP now owns 3,398,649 shares of the conglomerate’s stock valued at $849,195,000 after buying an additional 85,081 shares during the period. Finally, Massachusetts Financial Services Co. MA raised its position in Danaher by 22.7% during the second quarter. Massachusetts Financial Services Co. MA now owns 3,047,728 shares of the conglomerate’s stock valued at $761,475,000 after buying an additional 563,546 shares during the period. 79.05% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Danaher

In other Danaher news, SVP Georgeann Couchara sold 952 shares of the company’s stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the transaction, the senior vice president now owns 4,212 shares of the company’s stock, valued at $1,130,374.44. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In other news, SVP Brian W. Ellis sold 9,600 shares of the stock in a transaction that occurred on Thursday, July 25th. The stock was sold at an average price of $275.16, for a total value of $2,641,536.00. Following the completion of the transaction, the senior vice president now directly owns 20,230 shares of the company’s stock, valued at approximately $5,566,486.80. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Georgeann Couchara sold 952 shares of the stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the transaction, the senior vice president now directly owns 4,212 shares of the company’s stock, valued at approximately $1,130,374.44. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 39,659 shares of company stock valued at $11,042,433 in the last quarter. Corporate insiders own 11.10% of the company’s stock.

Danaher Price Performance

Shares of NYSE:DHR opened at $267.99 on Thursday. The business has a 50 day moving average price of $270.53 and a 200 day moving average price of $259.65. Danaher Co. has a twelve month low of $182.09 and a twelve month high of $281.70. The company has a market cap of $198.50 billion, a price-to-earnings ratio of 45.42, a PEG ratio of 4.49 and a beta of 0.83. The company has a quick ratio of 1.04, a current ratio of 1.43 and a debt-to-equity ratio of 0.33.

Danaher (NYSE:DHR) last announced its earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share for the quarter, beating the consensus estimate of $1.57 by $0.15. The firm had revenue of $5.74 billion during the quarter, compared to the consensus estimate of $5.59 billion. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The firm’s revenue for the quarter was down 2.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.05 EPS. Research analysts predict that Danaher Co. will post 7.59 earnings per share for the current year.

Danaher Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, October 25th. Shareholders of record on Friday, September 27th will be issued a $0.27 dividend. The ex-dividend date of this dividend is Friday, September 27th. This represents a $1.08 annualized dividend and a yield of 0.40%. Danaher’s dividend payout ratio (DPR) is 18.31%.

Analysts Set New Price Targets

Several research analysts recently weighed in on DHR shares. StockNews.com lowered Danaher from a “buy” rating to a “hold” rating in a research report on Tuesday, June 25th. Royal Bank of Canada reissued an “outperform” rating and set a $300.00 price target on shares of Danaher in a research report on Friday, September 6th. The Goldman Sachs Group boosted their target price on Danaher from $225.00 to $250.00 and gave the company a “neutral” rating in a research note on Wednesday, July 24th. Wells Fargo & Company started coverage on Danaher in a research note on Tuesday, August 27th. They issued an “equal weight” rating and a $280.00 target price on the stock. Finally, Barclays boosted their target price on Danaher from $270.00 to $285.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 24th. Seven research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $282.12.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.